US 12,257,259 B2
Nutritional composition comprising 2′-Fucosyllactose (2′ FL) to improve the gastrointestinal barrier
Clara Lucia Garcia-Rodenas, Forel (CH); Jane Mea M Natividad, Lausanne (CH); Andreas Rytz, Carrouge (CH); Sami Damak, Lausanne (CH); Norbert Sprenger, Savigny (CH); Francis Foata, La Conversion (CH); Florence Rochat, Montreux (CH); and Claire Laurence Lucie Marie Boulange, Lausanne (CH)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 17/416,571
Filed by SOCIETE DES PRODUITS NESTLE S.A., Vevey (CH)
PCT Filed Dec. 11, 2019, PCT No. PCT/EP2019/084572
§ 371(c)(1), (2) Date Jun. 21, 2021,
PCT Pub. No. WO2020/126726, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 18215208 (EP), filed on Dec. 21, 2018.
Prior Publication US 2022/0079963 A1, Mar. 17, 2022
Int. Cl. A61K 31/702 (2006.01); A23L 33/00 (2016.01); A23L 33/125 (2016.01); A61K 31/07 (2006.01); A61K 31/122 (2006.01); A61K 31/14 (2006.01); A61K 31/197 (2006.01); A61K 31/202 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/4188 (2006.01); A61K 31/4415 (2006.01); A61K 31/455 (2006.01); A61K 31/51 (2006.01); A61K 31/519 (2006.01); A61K 31/525 (2006.01); A61K 31/593 (2006.01); A61K 31/714 (2006.01); A61K 33/00 (2006.01); A61K 33/04 (2006.01); A61K 33/06 (2006.01); A61K 33/18 (2006.01); A61K 33/20 (2006.01); A61K 33/26 (2006.01); A61K 33/30 (2006.01); A61K 33/32 (2006.01); A61K 33/34 (2006.01); A61K 33/42 (2006.01); A61K 47/26 (2006.01); A61P 1/00 (2006.01); A61P 3/02 (2006.01)
CPC A61K 31/702 (2013.01) [A23L 33/125 (2016.08); A23L 33/40 (2016.08); A61K 31/07 (2013.01); A61K 31/122 (2013.01); A61K 31/14 (2013.01); A61K 31/197 (2013.01); A61K 31/202 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/4188 (2013.01); A61K 31/4415 (2013.01); A61K 31/455 (2013.01); A61K 31/51 (2013.01); A61K 31/519 (2013.01); A61K 31/525 (2013.01); A61K 31/593 (2013.01); A61K 31/714 (2013.01); A61K 33/00 (2013.01); A61K 33/04 (2013.01); A61K 33/06 (2013.01); A61K 33/18 (2013.01); A61K 33/20 (2013.01); A61K 33/26 (2013.01); A61K 33/30 (2013.01); A61K 33/32 (2013.01); A61K 33/34 (2013.01); A61K 33/42 (2013.01); A61K 47/26 (2013.01); A61P 1/00 (2018.01); A61P 3/02 (2018.01); A23V 2002/00 (2013.01)] 11 Claims
 
1. A method for improving a gastrointestinal barrier, inhibiting barrier dysfunction, prevention of barrier leakiness, protecting tight junction structure, or protecting intestinal epithelial lining integrity of an infant selected from the group consisting of premature, small for gestational age and low birth weight babies, the method comprising administering a synthetic nutritional composition comprising 2′-Fucosyllactose (2′FL) to the infant,
wherein the improving the gastrointestinal barrier comprises improving barrier protection,
wherein the improving, the inhibiting and/or the protecting is achieved by increasing kynurenic acid production by microbiota of the infant consuming the synthetic nutritional composition, and
wherein the 2′FL is present in an amount of 0.25 to 1.9 g/L or 0.15 to 1.5 g/100 g of the synthetic nutritional composition on a dry weight basis.